Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.
Pulike Biological Engineering (603566) - Net Assets
Latest net assets as of September 2025: CN¥2.58 Billion CNY
Based on the latest financial reports, Pulike Biological Engineering (603566) has net assets worth CN¥2.58 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.09 Billion) and total liabilities (CN¥513.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.58 Billion |
| % of Total Assets | 83.4% |
| Annual Growth Rate | 17.0% |
| 5-Year Change | 53.6% |
| 10-Year Change | 96.39% |
| Growth Volatility | 29.93 |
Pulike Biological Engineering - Net Assets Trend (2009–2024)
This chart illustrates how Pulike Biological Engineering's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pulike Biological Engineering (2009–2024)
The table below shows the annual net assets of Pulike Biological Engineering from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.63 Billion | -3.59% |
| 2023-12-31 | CN¥2.72 Billion | -2.67% |
| 2022-12-31 | CN¥2.80 Billion | +55.43% |
| 2021-12-31 | CN¥1.80 Billion | +5.31% |
| 2020-12-31 | CN¥1.71 Billion | +3.11% |
| 2019-12-31 | CN¥1.66 Billion | +1.37% |
| 2018-12-31 | CN¥1.64 Billion | +4.25% |
| 2017-12-31 | CN¥1.57 Billion | +5.94% |
| 2016-12-31 | CN¥1.48 Billion | +10.75% |
| 2015-12-31 | CN¥1.34 Billion | +95.62% |
| 2014-12-31 | CN¥683.59 Million | +13.30% |
| 2013-12-31 | CN¥603.33 Million | +36.97% |
| 2012-12-31 | CN¥440.47 Million | +41.51% |
| 2011-12-31 | CN¥311.26 Million | +58.90% |
| 2010-12-31 | CN¥195.88 Million | -21.35% |
| 2009-12-31 | CN¥249.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pulike Biological Engineering's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 470.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥962.83 Million | 36.66% |
| Common Stock | CN¥346.06 Million | 13.18% |
| Other Components | CN¥1.32 Billion | 50.16% |
| Total Equity | CN¥2.63 Billion | 100.00% |
Pulike Biological Engineering Competitors by Market Cap
The table below lists competitors of Pulike Biological Engineering ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Phoenix Telecom Technology Co. Ltd.
SHE:301191
|
$382.39 Million |
|
Rigol Technologies Co. Ltd. A
SHG:688337
|
$382.41 Million |
|
SDIC Zhonglu Fruit Juice Co Ltd
SHG:600962
|
$382.44 Million |
|
TPK Holding Co Ltd
TW:3673
|
$382.51 Million |
|
Jiangsu Xiuqiang Glasswork Co
SHE:300160
|
$382.15 Million |
|
J.Pond Precision Technology Co. Ltd. A
SHE:301326
|
$382.12 Million |
|
BizConf Telecom Co Ltd
SHE:300578
|
$382.10 Million |
|
Changchai Co Ltd
SHE:000570
|
$381.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pulike Biological Engineering's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,723,874,771 to 2,626,091,904, a change of -97,782,867 (-3.6%).
- Net income of 92,806,499 contributed positively to equity growth.
- Dividend payments of 137,845,229 reduced retained earnings.
- Share repurchases of 52,695,324 reduced equity.
- Other comprehensive income decreased equity by 206,511,785.
- Other factors increased equity by 206,462,972.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥92.81 Million | +3.53% |
| Dividends Paid | CN¥137.85 Million | -5.25% |
| Share Repurchases | CN¥52.70 Million | -2.01% |
| Other Comprehensive Income | CN¥-206.51 Million | -7.86% |
| Other Changes | CN¥206.46 Million | +7.86% |
| Total Change | CN¥- | -3.59% |
Book Value vs Market Value Analysis
This analysis compares Pulike Biological Engineering's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.36x to 1.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥1.04 | CN¥13.84 | x |
| 2010-12-31 | CN¥0.81 | CN¥13.84 | x |
| 2011-12-31 | CN¥1.29 | CN¥13.84 | x |
| 2012-12-31 | CN¥1.84 | CN¥13.84 | x |
| 2013-12-31 | CN¥2.52 | CN¥13.84 | x |
| 2014-12-31 | CN¥2.85 | CN¥13.84 | x |
| 2015-12-31 | CN¥4.62 | CN¥13.84 | x |
| 2016-12-31 | CN¥4.65 | CN¥13.84 | x |
| 2017-12-31 | CN¥4.95 | CN¥13.84 | x |
| 2018-12-31 | CN¥5.07 | CN¥13.84 | x |
| 2019-12-31 | CN¥5.16 | CN¥13.84 | x |
| 2020-12-31 | CN¥5.40 | CN¥13.84 | x |
| 2021-12-31 | CN¥5.72 | CN¥13.84 | x |
| 2022-12-31 | CN¥8.68 | CN¥13.84 | x |
| 2023-12-31 | CN¥7.80 | CN¥13.84 | x |
| 2024-12-31 | CN¥7.64 | CN¥13.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pulike Biological Engineering utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.90%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.18x
- Recent ROE (3.53%) is below the historical average (17.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 37.24% | 34.82% | 0.82x | 1.31x | CN¥67.85 Million |
| 2010 | 42.88% | 28.73% | 0.66x | 2.25x | CN¥64.40 Million |
| 2011 | 37.07% | 27.96% | 0.82x | 1.61x | CN¥84.25 Million |
| 2012 | 29.34% | 30.95% | 0.72x | 1.32x | CN¥85.17 Million |
| 2013 | 26.99% | 34.50% | 0.65x | 1.21x | CN¥102.53 Million |
| 2014 | 20.52% | 29.48% | 0.57x | 1.23x | CN¥71.90 Million |
| 2015 | 10.60% | 29.64% | 0.32x | 1.12x | CN¥8.02 Million |
| 2016 | 12.69% | 32.24% | 0.34x | 1.17x | CN¥39.91 Million |
| 2017 | 7.28% | 21.55% | 0.29x | 1.15x | CN¥-42.70 Million |
| 2018 | 8.29% | 22.30% | 0.32x | 1.16x | CN¥-27.94 Million |
| 2019 | 6.59% | 16.47% | 0.35x | 1.15x | CN¥-56.56 Million |
| 2020 | 12.67% | 23.33% | 0.46x | 1.19x | CN¥45.70 Million |
| 2021 | 13.56% | 22.22% | 0.51x | 1.20x | CN¥64.09 Million |
| 2022 | 6.00% | 13.67% | 0.36x | 1.21x | CN¥-112.03 Million |
| 2023 | 6.41% | 13.93% | 0.38x | 1.20x | CN¥-97.87 Million |
| 2024 | 3.53% | 8.90% | 0.34x | 1.18x | CN¥-169.80 Million |
Industry Comparison
This section compares Pulike Biological Engineering's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pulike Biological Engineering (603566) | CN¥2.58 Billion | 37.24% | 0.20x | $382.17 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |